OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
| Autor: | Robson, M.E. *, Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., Wu, W., Goessl, C., Runswick, S. †, Domchek, S.M. |
|---|---|
| Zdroj: | In Annals of Oncology April 2019 30(4):558-566 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|